Cargando…
Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care‐based cohort study, with economic assessment of patient outcomes
AIMS: To describe the relative health and economic outcomes associated with different second‐line therapeutic approaches to manage glycaemia in older type 2 diabetes patients requiring escalation from metformin monotherapy. MATERIALS AND METHODS: The Clinical Practice Research Datalink database was...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412932/ https://www.ncbi.nlm.nih.gov/pubmed/28026911 http://dx.doi.org/10.1111/dom.12867 |
_version_ | 1783233105532813312 |
---|---|
author | Gordon, Jason McEwan, Phil Evans, Marc Puelles, Jorge Sinclair, Alan |
author_facet | Gordon, Jason McEwan, Phil Evans, Marc Puelles, Jorge Sinclair, Alan |
author_sort | Gordon, Jason |
collection | PubMed |
description | AIMS: To describe the relative health and economic outcomes associated with different second‐line therapeutic approaches to manage glycaemia in older type 2 diabetes patients requiring escalation from metformin monotherapy. MATERIALS AND METHODS: The Clinical Practice Research Datalink database was used to inform a retrospective observational cohort study of patients with type 2 diabetes treated with metformin monotherapy requiring escalation (addition or switch) to a second‐line oral regimen from January 1, 2008 to December 31, 2014. Primary outcomes included time to first event (any event, myocardial infarction [MI], stroke, or composite of MI/stroke [major adverse cardiovascular event; MACE]) and total event rate. The health economic consequences associated with the choice of second‐line treatment in older patients were assessed using the CORE Diabetes Model. RESULTS: A total of 10 484 patients were included; the majority escalated to second‐line treatment with metformin + sulphonylurea (SU; 42%) or switched to SU monotherapy (28%). In multivariate adjusted analyses, total event rates for MACE with metformin + dipeptidyl peptidase‐4 (DPP‐4) inhibitor were significantly lower than with metformin + SU (0.61, 95% confidence interval [CI] 0.39‐0.98), driven by a lower MI rate in the metformin + DPP‐4 inhibitor group (0.52, 95% CI 0.27‐0.99). Economic analyses estimated that metformin + DPP‐4 inhibitor treatment was associated with the largest gain in health benefit, and cost‐effectiveness ratios were favourable (<£30 000 per quality‐adjusted life‐year) for all second‐line treatment scenarios. CONCLUSIONS: With respect to treatment choice, data from the present study support the notion of prescribing beyond metformin + SU, as alternative regimens have been shown to be associated with reduced outcomes risk and value for money. |
format | Online Article Text |
id | pubmed-5412932 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-54129322017-05-19 Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care‐based cohort study, with economic assessment of patient outcomes Gordon, Jason McEwan, Phil Evans, Marc Puelles, Jorge Sinclair, Alan Diabetes Obes Metab Original Articles AIMS: To describe the relative health and economic outcomes associated with different second‐line therapeutic approaches to manage glycaemia in older type 2 diabetes patients requiring escalation from metformin monotherapy. MATERIALS AND METHODS: The Clinical Practice Research Datalink database was used to inform a retrospective observational cohort study of patients with type 2 diabetes treated with metformin monotherapy requiring escalation (addition or switch) to a second‐line oral regimen from January 1, 2008 to December 31, 2014. Primary outcomes included time to first event (any event, myocardial infarction [MI], stroke, or composite of MI/stroke [major adverse cardiovascular event; MACE]) and total event rate. The health economic consequences associated with the choice of second‐line treatment in older patients were assessed using the CORE Diabetes Model. RESULTS: A total of 10 484 patients were included; the majority escalated to second‐line treatment with metformin + sulphonylurea (SU; 42%) or switched to SU monotherapy (28%). In multivariate adjusted analyses, total event rates for MACE with metformin + dipeptidyl peptidase‐4 (DPP‐4) inhibitor were significantly lower than with metformin + SU (0.61, 95% confidence interval [CI] 0.39‐0.98), driven by a lower MI rate in the metformin + DPP‐4 inhibitor group (0.52, 95% CI 0.27‐0.99). Economic analyses estimated that metformin + DPP‐4 inhibitor treatment was associated with the largest gain in health benefit, and cost‐effectiveness ratios were favourable (<£30 000 per quality‐adjusted life‐year) for all second‐line treatment scenarios. CONCLUSIONS: With respect to treatment choice, data from the present study support the notion of prescribing beyond metformin + SU, as alternative regimens have been shown to be associated with reduced outcomes risk and value for money. Blackwell Publishing Ltd 2017-02-23 2017-05 /pmc/articles/PMC5412932/ /pubmed/28026911 http://dx.doi.org/10.1111/dom.12867 Text en © 2016 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Gordon, Jason McEwan, Phil Evans, Marc Puelles, Jorge Sinclair, Alan Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care‐based cohort study, with economic assessment of patient outcomes |
title | Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care‐based cohort study, with economic assessment of patient outcomes |
title_full | Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care‐based cohort study, with economic assessment of patient outcomes |
title_fullStr | Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care‐based cohort study, with economic assessment of patient outcomes |
title_full_unstemmed | Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care‐based cohort study, with economic assessment of patient outcomes |
title_short | Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care‐based cohort study, with economic assessment of patient outcomes |
title_sort | managing glycaemia in older people with type 2 diabetes: a retrospective, primary care‐based cohort study, with economic assessment of patient outcomes |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412932/ https://www.ncbi.nlm.nih.gov/pubmed/28026911 http://dx.doi.org/10.1111/dom.12867 |
work_keys_str_mv | AT gordonjason managingglycaemiainolderpeoplewithtype2diabetesaretrospectiveprimarycarebasedcohortstudywitheconomicassessmentofpatientoutcomes AT mcewanphil managingglycaemiainolderpeoplewithtype2diabetesaretrospectiveprimarycarebasedcohortstudywitheconomicassessmentofpatientoutcomes AT evansmarc managingglycaemiainolderpeoplewithtype2diabetesaretrospectiveprimarycarebasedcohortstudywitheconomicassessmentofpatientoutcomes AT puellesjorge managingglycaemiainolderpeoplewithtype2diabetesaretrospectiveprimarycarebasedcohortstudywitheconomicassessmentofpatientoutcomes AT sinclairalan managingglycaemiainolderpeoplewithtype2diabetesaretrospectiveprimarycarebasedcohortstudywitheconomicassessmentofpatientoutcomes |